Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5356 | Miltirone |
| Miltirone is a CYPs inhibition, it has been characterized as a low-affinity ligand for central benzodiazepine receptors, it might ameliorate the symptoms associated with discontinuation of long-term administration of ethanol or of other positive modulators of the GABA A receptor. Miltirone possesses significant anticancer, antibacterial, antioxidant, and anti-inflammatory activities, the hepatocyte metabolism is the major route of clearance for miltirone. Miltirone is collateral sensitive in multidrug-resistant P-gp-overexpressing cells, induces G2/M arrest, and triggeres apoptosis via ROS-generated breakdown of MMP and DNA damage. Miltirone has antiprotozoal activity against T. brucei rhodesiense STIB 900. | |
| BCN5358 | Digitoxin |
| The cardiac glycosides digitoxin and digoxin have been used in cardiac diseases for many years, digitoxin also has growth inhibition activity in three human cancer cell line, digitoxin activates pro-apoptotic, anti-proliferative signaling cascades and cell cycle arrest. Digitoxin could as a candidate drug for suppressing IL-8-dependent lung inflammation in cystic fibrosis (CF), it can suppress hypersecretion of IL-8 from cultured cystic fibrosis (CF) lung epithelial cells, the specific mechanism is to block phosphorylation of the inhibitor of NF-kappa.Digitoxin actively inhibits Herpes simplex virus type 1 (HSV-1) replication with a 50% effective concentration (EC(50)) of 0.05 microM, the inhibitory effects of digitoxin are likely to be introduced at the early stage of HSV-1 replication and the virus release stage. | |
| BCN5359 | Digoxin |
| Digoxin is a classical Na,K-ATPase inhibitor, with selectivity for the α2β3 isoform over the common α1β1 isoform, used in the treatment of atrial fibrillation and heart failure. Digoxin and other cardiac glycosides can inhibit hypoxia-inducible factor 1 (HIF-1)α synthesis and block tumor growth. | |
| BCN5360 | Gracillin |
| Gracillin has anti-tumor activity, can induce cell cycle arrest, oxidative stress, and apoptosis in HL60 cells, and has the potential to be developed as an antitumor agent. | |
| BCN5363 | Oroxylin A |
| Oroxylin A has anticancer,.anti-inflammation, antithrombotic,antibacterial, anti-pruritic effects, it can inhibit LPS-induced iNOS and COX-2 gene expression by blocking NF-κB activation. Oroxylin A reverses MDR by G2/M arrest and the underlying mechanism attributed to the suppression of P-gp expression via Chk2/P53/NF-κB signaling pathway. Oroxylin A facilitates memory consolidation through brain-derived neurotrophic factor (BDNF)-TrkB signaling. | |
